INCB161734 + cetuximab

INCB161734 + cetuximab is an investigational combination therapy in clinical development for the treatment of advanced or metastatic solid tumors harboring KRAS G12D mutations. **INCB161734** is a novel, potent, and orally bioavailable small-molecule inhibitor that selectively targets the KRAS G12D mutant protein, inhibiting oncogenic signaling through pathways such as ERK and PI3K. INCB161734 binds to both GDP- and GTP-bound forms of KRAS G12D with high selectivity (>80-fold over wildtype) and downstream leads to cell-cycle arrest and apoptosis in G12D mutant tumors. **Cetuximab** is a recombinant, chimeric monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR), blocking EGFR-mediated signaling implicated in cancer cell proliferation and survival. The combination is being evaluated for safety and antitumor activity in early-phase clinical trials, particularly for tumors known to be driven by KRAS G12D, such as pancreatic and colorectal cancers[1][2][3][5].